Enovis (NYSE:ENOV) Updates FY 2026 Earnings Guidance

Enovis (NYSE:ENOV) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 3.520-3.730 for the period, compared to the consensus earnings per share estimate of 3.540. The company issued revenue guidance of $2.3 billion-$2.4 billion, compared to the consensus revenue estimate of $2.3 billion.

Enovis Trading Down 3.0%

ENOV traded down $0.78 during trading on Friday, hitting $25.53. 501,440 shares of the company’s stock were exchanged, compared to its average volume of 1,095,029. The stock has a 50 day moving average price of $24.54 and a 200 day moving average price of $23.95. Enovis has a 1 year low of $19.14 and a 1 year high of $34.28. The company has a current ratio of 2.04, a quick ratio of 1.05 and a debt-to-equity ratio of 0.87. The firm has a market cap of $1.47 billion, a P/E ratio of -1.28 and a beta of 1.34.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.05. The firm had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. Enovis’s quarterly revenue was up 3.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, analysts expect that Enovis will post 3.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ENOV has been the topic of several research reports. Wall Street Zen raised Enovis from a “hold” rating to a “buy” rating in a research report on Monday, July 6th. BMO Capital Markets restated an “outperform” rating and issued a $30.00 price objective on shares of Enovis in a research note on Friday. BTIG Research raised their price objective on shares of Enovis from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday. Weiss Ratings raised shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. Finally, William Blair initiated coverage on Enovis in a research report on Friday, April 17th. They set an “outperform” rating on the stock. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $42.00.

Insider Buying and Selling at Enovis

In other Enovis news, insider Oliver Engert purchased 1,200 shares of Enovis stock in a transaction that occurred on Thursday, June 11th. The stock was acquired at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the acquisition, the insider owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. In the last three months, insiders bought 4,200 shares of company stock valued at $92,084. 2.90% of the stock is owned by company insiders.

Key Stories Impacting Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis reported second-quarter adjusted EPS of $0.90, above the $0.85 analyst consensus and up from $0.79 a year earlier. Revenue of $582.8 million also slightly exceeded estimates and increased 3.2% year over year. Enovis Second Quarter Earnings Results
• Positive Sentiment: Reconstructive sales were a key growth driver, rising 8% on a reported basis and 6% organically. Total second-quarter sales grew 3% reported and 5% organically, supporting the company’s long-term growth strategy. Enovis Announces Second Quarter 2026 Results
• Positive Sentiment: BTIG Research raised its price target from $39 to $40 and maintained a Buy rating, signaling continued analyst confidence in Enovis’ potential despite near-term execution concerns. BTIG Research Price Target Report
• Neutral Sentiment: Management reaffirmed its full-year 2026 outlook, including revenue guidance of $2.3 billion to $2.4 billion and EPS guidance of $3.52 to $3.73. The EPS range brackets the roughly $3.54 consensus estimate, offering limited near-term guidance upside. Enovis 2026 Second Quarter Results Presentation
• Negative Sentiment: Investors reacted negatively to commentary characterizing quarterly performance as softer than expected. Although the company beat consensus estimates, the modest overall sales growth and lack of an upward guidance revision appear to have raised concerns about momentum and execution. Enovis Shares Drop After Second Quarter Earnings

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ENOV. Rubric Capital Management LP acquired a new position in shares of Enovis in the 3rd quarter valued at about $83,435,000. AQR Capital Management LLC increased its position in Enovis by 682.6% in the 2nd quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock valued at $15,627,000 after buying an additional 434,646 shares in the last quarter. Paradigm Capital Management Inc. NY raised its position in shares of Enovis by 41.6% during the second quarter. Paradigm Capital Management Inc. NY now owns 1,113,300 shares of the company’s stock worth $34,913,000 after purchasing an additional 326,900 shares during the period. ExodusPoint Capital Management LP increased its position in shares of Enovis by 163.4% during the fourth quarter. ExodusPoint Capital Management LP now owns 508,971 shares of the company’s stock worth $13,559,000 after acquiring an additional 315,711 shares in the last quarter. Finally, Soleus Capital Management L.P. bought a new position in Enovis in the 2nd quarter valued at about $9,878,000. 98.45% of the stock is currently owned by institutional investors and hedge funds.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.